Sorrento Therapeutics Inc.

10/27/2021 | Press release | Distributed by Public on 10/27/2021 12:32

Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients